

PRODUCT INFORMATION



1-Palmitoyl-d₉-2-hydroxy-sn-glycero-3-PA

Item No. 33479

CAS Registry No.: 2830282-77-2

Formal Name: hexadecanoic acid-13,13,14,14,15,15,16,16,16-d₉,
2R-hydroxy-3-(phosphonoxy)propyl ester

Synonyms: 1-Hexadecanoyl-d₉-2-hydroxy-sn-glycero-3-
phosphate, 16:0-d₉ LPA, LPA 16:0-d₉, PA(16:0-d₉/0:0),
1-Palmitoyl-d₉ LPA, 1-Palmitoyl-d₉ Lysophosphatidic Acid

MF: C₁₉H₃₀D₉O₇P

FW: 419.5

Chemical Purity: ≥95% (9:1 mixture of 1':2' acyl chain positional isomers)
(1-Palmitoyl Lysophosphatidic Acid)

Deuterium


Incorporation: ≥99% deuterated forms (d₁-d₉); ≤1% d₀

Supplied as: A 250 µg/ml solution in ethanol

Storage: -20°C

Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

1-Palmitoyl-d₉-2-hydroxy-sn-glycero-3-PA (1-palmitoyl-d₉ LPA) is intended for use as an internal standard for the quantification of 1-palmitoyl LPA (Item Nos. 10010094 | 10010290) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Description

1-Palmitoyl LPA is an analog of LPA that contains palmitic acid (Item No. 10006627) at the sn-1 position. It induces reporter gene expression in PC12 cells expressing human lysophosphatidic acid receptor 4 (LPA₄) when used at concentrations ranging from 0.01 to 10 µM.¹ 1-Palmitoyl LPA (12-300 µM) induces aggregation of isolated human platelets, an effect that can be reversed by prostaglandin E₁ (PGE₁; Item No. 13010), theophylline (Item No. 23760), or EDTA.² It also binds to calcium and magnesium and enhances the activity of ampicillin (Item No. 14417), piperacillin (Item No. 20766), and ceftazidime (Item No. 14828) against *P. aeruginosa* isolates from patients with cystic fibrosis.³

References

1. Noguchi, K., Ishii, S., and Shimizu, T. Identification of p2y₉/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. *J. Biol. Chem.* **278**(28), 25600-25606 (2003).
2. Gerrard, J.M., Kindom, S.E., Peterson, D.A., et al. Lysophosphatidic acids. Influence on platelet aggregation and intracellular calcium flux. *Am. J. Pathol.* **96**(2), 423-438 (1979).
3. Krogfelt, K.A., Utley, M., Krivan, H.C., et al. Specific phospholipids enhance the activity of β-lactam antibiotics against *Pseudomonas aeruginosa*. *J. Antimicrob. Chemother.* **46**(3), 377-384 (2000).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/20/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM